Proportion with complete resolution of a target tophus · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Mean sUA at end of 12 months · participants with tophi in gout
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Psychological distress Measures: ‐ Parenting Stress Index (PSI‐SF) ‐ Psychiatric Symptom Index (PSI) ‐ PSI anxiety sub‐scale ‐ State anxiety inventory ‐ Center for Epidemological Studies Depression Scale (CES‐D) ‐ Profile of Mood State Inventory (... · parents and carers of children with complex needs
1 finding from 1 review
Confidence and self‐efficacy · parents and carers of children with complex needs
1 finding from 1 review
Perception of coping · parents and carers of children with complex needs
1 finding from 1 review
Quality of life Measures: ‐ Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) ‐ Beach Centre Family Quality of Life Scale (higher scores = better quality of life) Timing of · parents and carers of children with complex needs
1 finding from 1 review
Family functioning · parents and carers of children with complex needs
1 finding from 1 review
Perceived social support · parents and carers of children with complex needs
1 finding from 1 review
Confidence and skill at navigating medical services · parents and carers of children with complex needs
1 finding from 1 review
Adverse events · parents and carers of children with complex needs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Registration behaviour: ICC adjusted (dichotomous) · increasing solid organ donation registration
The intervention may leads to higher registration behaviour: ICC adjusted (dichotomous) (low certainty).
1 finding from 1 review